Case Report
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Oct 18, 2017; 9(29): 1158-1165
Published online Oct 18, 2017. doi: 10.4254/wjh.v9.i29.1158
Bone metastases as initial presentation of hepatocellular carcinoma
Luzdivina Monteserin, Alicia Mesa, Maria Soledad Fernandez-Garcia, Arantza Gadanon-Garcia, Manuel Rodriguez, María Varela
Luzdivina Monteserin, Department of Gastroenterology and Hepatology, Complejo Asistencial Universitario de León, 24001 León, Spain
Alicia Mesa, Department of Radiology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain
Maria Soledad Fernandez-Garcia, Department of Pathology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain
Arantza Gadanon-Garcia, Department of Traumatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain
Manuel Rodriguez, María Varela, Liver Unit, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain
Author contributions: Monteserin L, Mesa A and Fernandez-Garcia MS designed the report; Monteserin L, Gadanon-Garcia A and Varela M collected the patient’s clinical data; Rodriguez M and Varela M analyzed the data and wrote the paper.
Supported by Department of Gastroenterology and Hepatology of the Hospital Universitario Central de Asturias.
Institutional review board statement: The study was reviewed and approved by the Hospital Universitario Central de Asturias Institutional Review Board.
Informed consent statement: Informed consent was obtained prior to submission from the patients/relatives for publication of these case reports and all accompanying images.
Conflict-of-interest statement: Monteserin L, Mesa A, Fernandez-Garcia MS and Gadanon-Garcia A have nothing to declare; Rodriguez M has received fees for serving as a speaker and a consultant for Bristol, Gilead, Abbvie and MSD; Rodriguez M has received fees for serving as an advisory board member for Bayer; Varela M has received fees for serving as a speaker for BTG, Abbvie, Gilead and Bayer; Varela M has received fees for serving as an advisory board member for Bayer.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: María Varela, MD, PhD, Liver Unit, Hospital Universitario Central de Asturias, Avenida de Roma S/N, 33011 Oviedo, Spain. maria.varelac@sespa.es
Telephone: +34-985-108000 Fax: +34-985-108115
Received: March 10, 2017
Peer-review started: March 17, 2017
First decision: May 2, 2017
Revised: July 19, 2017
Accepted: September 3, 2017
Article in press: September 5, 2017
Published online: October 18, 2017
Core Tip

Core tip: Metastatic hepatocellular carcinoma should be included within the differential diagnoses of bone metastases of unknown origin, even in the absence of already known chronic liver disease.